GC-3111A is under clinical development by GC Biopharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GC-3111A’s likelihood of approval (LoA) and phase transition for Pertussis (Whooping Cough) took place on 03 Jul 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GC-3111A Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GC-3111A overview

GC-3111A is under development for the prevention of tetanus, diphtheria and pertussis (whooping cough). It is administered intramuscularly. It is a combined tetanus, diphtheria, acellular pertussis (adsorbed) vaccine for booster vaccination indicated for active immunization.

GC Biopharma overview

GC Biopharma, formerly known as GC Pharma, a subsidiary of Green Cross Holdings Corp, provides plasma protein therapeutics and vaccines. The company develops, manufactures, and markets a wide product portfolio comprising plasma derivatives including albumin, immunoglobulin, and antithrombin; vaccines for infectious diseases; prescription drugs for treating cardiovascular, respiratory, central nervous system (CNS), gastrointestinal and immunology diseases, musculoskeletal disorders, genetic disorders, metabolic disorders and hematological disorders; and Over-the-counter (OTC) drugs including anti-inflammatory drugs, anti-allergic products, and others. The company focuses its research and development activities on developing drugs for treatment of cancer, tuberculosis, and hunter syndrome, among others. GC Biopharma is headquartered Yongin, Gyeonggi-do, South Korea.

Quick View GC-3111A LOA Data

Report Segments
  • Innovator
Drug Name
  • GC-3111A
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.